$LEXX
Lexaria Bioscience Corp. Stock $lexx

$lexx Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000164033420001650 Filed on June 29, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q3
Revenue	$130.0K	$36.42K	$130.0K
YoY Change	0.0%	-39.23%	30.0%
Cost Of Revenue	$10.00K	$20.32K	$10.00K
YoY Change	0.0%	556.3%
Gross Profit	$120.0K	$16.10K	$110.0K
YoY Change	9.09%	-71.67%	22.22%
Gross Profit Margin	92.31%	44.21%	84.62%
Selling, General & Admin	$800.0K	$1.390M	$1.020M
YoY Change	-21.57%	40.4%	-8.11%
% of Gross Profit	666.67%	8631.4%	927.27%
Research & Development	$70.00K	$24.56K	$160.0K
YoY Change	-56.25%	-89.37%	-23.81%
% of Gross Profit	58.33%	152.49%	145.45%
Depreciation & Amortization	$30.00K	$28.08K	$30.00K
YoY Change	0.0%	23.89%
% of Gross Profit	25.0%	174.37%	27.27%
Operating Expenses	$900.0K	$1.426M	$1.210M
YoY Change	-25.62%	14.59%	-8.33%
Operating Profit	-$780.0K	-$1.410M	-$1.100M
YoY Change	-29.09%	18.72%	-10.57%
Interest Expense	$0.00	$0.00	-$10.00K
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$770.0K	-$1.390M	-$1.120M
YoY Change	-31.25%	16.81%	-8.94%
Income Tax
% Of Pretax Income
Net Earnings	-$715.0K	-$1.391M	-$1.080M
YoY Change	-33.8%	18.86%	-11.48%
Net Earnings / Revenue	-549.97%	-3818.06%	-830.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$7.896K	-$491.0K	-$412.2K
COMMON SHARES
Basic Shares Outstanding	89.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.310M	$2.059M	$1.350M
YoY Change	-2.96%	-0.53%	-22.41%
Cash & Equivalents	$1.294M	$2.034M	$1.285M
Short-Term Investments	$20.00K	$25.00K	$60.00K
Other Short-Term Assets	$290.0K	$90.00K	$70.00K
YoY Change	314.29%	-25.0%	-63.16%
Inventory	$116.9K	$132.9K	$127.4K
Prepaid Expenses	$182.1K	$88.94K	$68.93K
Receivables	$313.9K	$254.0K	$273.1K
Other Receivables	$130.0K	$230.0K	$260.0K
Total Short-Term Assets	$1.926M	$2.528M	$1.819M
YoY Change	5.89%	-3.14%	-20.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$483.4K	$511.3K	$591.3K
YoY Change	-18.25%	-16.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$902.3K	$792.2K	$856.4K
YoY Change	5.36%	-6.81%	470.93%
TOTAL ASSETS
Total Short-Term Assets	$1.926M	$2.528M	$1.819M
Total Long-Term Assets	$902.3K	$792.2K	$856.4K
Total Assets	$2.828M	$3.320M	$2.675M
YoY Change	5.72%	-4.04%	10.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$50.00K	$40.00K	$30.00K
YoY Change	66.67%	-55.56%	-25.0%
Accrued Expenses	$70.00K	$10.00K	$100.0K
YoY Change	-30.0%	-50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$225.9K	$90.97K	$184.5K
YoY Change	22.44%	-30.02%	361.27%
LONG-TERM LIABILITIES
Long-Term Debt	$30.00K	$30.00K	$0.00
YoY Change
Other Long-Term Liabilities	$90.00K
YoY Change
Total Long-Term Liabilities	$120.1K	$28.76K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$225.9K	$90.97K	$184.5K
Total Long-Term Liabilities	$120.1K	$28.76K	$0.00
Total Liabilities	$346.0K	$119.7K	$184.5K
YoY Change	87.52%	-57.24%	361.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.80M	-$27.09M	-$23.87M
YoY Change	16.48%
Common Stock	$3.001K	$89.59K	$78.79K
YoY Change	-96.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.482M	$3.201M	$2.491M
YoY Change
Total Liabilities & Shareholders Equity	$2.828M	$3.320M	$2.675M
YoY Change	5.72%	-4.04%	10.09%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q3
OPERATING ACTIVITIES
Net Income	-$715.0K	-$1.391M	-$1.080M
YoY Change	-33.8%	18.86%	-11.48%
Depreciation, Depletion And Amortization	$30.00K	$28.08K	$30.00K
YoY Change	0.0%	23.89%
Cash From Operating Activities	-$680.0K	-$610.0K	-$740.0K
YoY Change	-8.11%	-44.55%	-11.9%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K	-$10.00K
YoY Change	0.0%	-95.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	-$20.00K
YoY Change	-100.0%	-100.96%	-33.33%
Cash From Investing Activities	-$20.00K	$0.00	-$30.00K
YoY Change	-33.33%	-100.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00K	1.910M	60.00K
YoY Change	-166.67%	54.03%	-88.68%
NET CHANGE
Cash From Operating Activities	-680.0K	-610.0K	-740.0K
Cash From Investing Activities	-20.00K	0.000	-30.00K
Cash From Financing Activities	-40.00K	1.910M	60.00K
Net Change In Cash	-740.0K	1.300M	-710.0K
YoY Change	4.23%	-218.18%	108.82%
FREE CASH FLOW
Cash From Operating Activities	-$680.0K	-$610.0K	-$740.0K
Capital Expenditures	-$10.00K	-$10.00K	-$10.00K
Free Cash Flow	-$670.0K	-$600.0K	-$730.0K
YoY Change	-8.22%	-33.33%	-13.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2020-05-31
	dei	Entity Registrant Name EntityRegistrantName	Lexaria Bioscience Corp.
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001348362
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2034011	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1285147	USD
	dei	Amendment Flag AmendmentFlag	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89587090	shares
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1727184	USD
CY2020Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18277	USD
CY2019Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	64214	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	253960	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273145	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	132923	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	127396	USD
CY2020Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88940	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	68927	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	2528111	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	1818829	USD
CY2020Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	280870	USD
CY2019Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	265127	USD
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	511281	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	591263	USD
CY2020Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	792151	USD
CY2019Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	856390	USD
CY2020Q2	us-gaap	Assets Assets	3320262	USD
CY2019Q3	us-gaap	Assets Assets	2675219	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	55127	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	136411	USD
CY2019Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	48096	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	90972	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	184507	USD
CY2020Q2	us-gaap	Loans Payable LoansPayable	28756	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	28756	USD
CY2020Q2	us-gaap	Liabilities Liabilities	119728	USD
CY2019Q3	us-gaap	Liabilities Liabilities	184507	USD
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89587090	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	78787134	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89587090	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	78787134	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	89587	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	78787	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30184383	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26172453	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27087240	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23868202	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	3186730	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2383038	USD
CY2020Q2	us-gaap	Minority Interest MinorityInterest	13804	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	107674	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3200534	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2490712	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2388186	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3320262	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2675219	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	86278	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7944	USD
	us-gaap	Gross Profit GrossProfit	164526	USD
	us-gaap	Gross Profit GrossProfit	89545	USD
	us-gaap	Professional Fees ProfessionalFees	43642	USD
CY2019	lxrp	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	17498	shares
CY2019	lxrp	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	1183062	shares
CY2019	lxrp	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	1.99
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1995843	USD
CY2020Q2	us-gaap	Deferred Revenue DeferredRevenue	6250	USD
CY2020Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	29595	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3414276	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3773464	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3324805	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2615135	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1922936	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81423	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59931	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250804	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97489	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20319	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3096	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	61104	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	56835	USD
CY2020Q2	us-gaap	Professional Fees ProfessionalFees	17113	USD
CY2019Q2	us-gaap	Professional Fees ProfessionalFees	4407	USD
	us-gaap	Professional Fees ProfessionalFees	31474	USD
CY2020Q2	us-gaap	Depreciation Depreciation	28081	USD
CY2019Q2	us-gaap	Depreciation Depreciation	22666	USD
	us-gaap	Depreciation Depreciation	83875	USD
	us-gaap	Depreciation Depreciation	34355	USD
CY2020Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	48513	USD
CY2019Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	114706	USD
CY2020Q2	lxrp	Bad Debts BadDebts	50000	USD
CY2020Q2	lxrp	Consulting Expenses ConsultingExpenses	944210	USD
CY2019Q2	lxrp	Consulting Expenses ConsultingExpenses	280893	USD
	lxrp	Consulting Expenses ConsultingExpenses	1949234	USD
	lxrp	Consulting Expenses ConsultingExpenses	1127311	USD
CY2019Q2	lxrp	Investor Relations InvestorRelations	62309	USD
CY2020Q2	us-gaap	Legal Fees LegalFees	149257	USD
CY2019Q2	us-gaap	Legal Fees LegalFees	192677	USD
	us-gaap	Legal Fees LegalFees	289614	USD
	us-gaap	Legal Fees LegalFees	546710	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55402	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81876	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24557	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	231035	USD
CY2020Q2	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	2566	USD
CY2019Q2	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	33371	USD
CY2020Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	125274	USD
CY2019Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	224544	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	303635	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	250171	USD
CY2020Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-18198	USD
CY2020Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	19654	USD
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	81445	USD
CY2019Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	45068	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	608	USD
CY2019Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	50870	USD
CY2019Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	82328	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	146538	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	280870	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	20007	USD
CY2019	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	122982	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4393	USD
CY2019Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	649400	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3286274	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2825325	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14148154	shares
CY2018Q3	lxrp	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.72
CY2019Q3	lxrp	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.38
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	265127	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58137	USD
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.56
	lxrp	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P3Y10M2D
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1887607	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	129498	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	399848	USD
	lxrp	Bad Debts BadDebts	50000	USD
	lxrp	Investor Relations InvestorRelations	21277	USD
	lxrp	Investor Relations InvestorRelations	62309	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	194529	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	207036	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	318577	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	394091	USD
	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	46178	USD
	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	72870	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-18198	USD
	us-gaap	Inventory Write Down InventoryWriteDown	8240	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80962902	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1139270	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	507310	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	131000	USD
CY2020Q2	us-gaap	Trading Securities Cost TradingSecuritiesCost	56250	USD
CY2019	us-gaap	Unrealized Gain On Securities UnrealizedGainOnSecurities	9335	USD
	us-gaap	Unrealized Gain On Securities UnrealizedGainOnSecurities	8953	USD
CY2019	us-gaap	Unrealized Loss On Securities UnrealizedLossOnSecurities	26973	USD
CY2020Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	33286	USD
CY2019Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	39143	USD
CY2020Q2	lxrp	Prepaid Research And Development PrepaidResearchAndDevelopment	25386	USD
CY2019Q3	lxrp	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2019Q3	us-gaap	Trading Securities Cost TradingSecuritiesCost	81250	USD
	us-gaap	Unrealized Loss On Securities UnrealizedLossOnSecurities	46926	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	52817	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30815	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13396	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	101042	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	20013	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	75513	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-18501	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	13140	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6250	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6802	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	28756	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2714627	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3273683	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2743383	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3273683	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	748864	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	268659	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	10459	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	682563	USD
CY2020Q2	lxrp	Warrants Issued For Service WarrantsIssuedForService	98081	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	1244771	USD
	us-gaap	Operating Expenses OperatingExpenses	3477434	USD
	us-gaap	Operating Expenses OperatingExpenses	3131983	USD
CY2019Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3713	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-20937	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1390653	USD
CY2020Q2	lxrp	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.56
	lxrp	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	750000	shares
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5808	USD
CY2020Q2	us-gaap	Inventory Write Down InventoryWriteDown	8240	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	1451757	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1187936	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3312908	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3042438	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1361381	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1171805	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3219038	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3021172	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-701391	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1147976	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1078248	USD
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-907313	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-950344	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-29272	USD
CY2019Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16131	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-93870	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-21266	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5135	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-37727	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83084634	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80550438	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77509193	shares
	us-gaap	Net Income Loss NetIncomeLoss	-3312908	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3042438	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	168833	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16333	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-70924	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-81284	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1981314	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2268946	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20007	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	99418	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	636661	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13205	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-736079	USD
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64044	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	443266	USD
CY2020Q2	lxrp	Trade And Deposits Receivable TradeAndDepositsReceivable	16958	USD
CY2019Q3	lxrp	Trade And Deposits Receivable TradeAndDepositsReceivable	5727	USD
CY2020Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	649400	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	138118	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	294293	USD
CY2018Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1470310	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	119382	USD
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	162414	USD
CY2019	lxrp	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	0.59
	lxrp	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	1.50
CY2019	lxrp	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	1626513	shares
CY2019	lxrp	Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice	0.49
	lxrp	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	12072829	shares
	lxrp	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	0.42
	lxrp	Share Based Compensation Arrangement By Share Based Payment Award Options Term Expiration ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTermExpiration	P5Y
CY2019Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	816020	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	110000	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	430000	shares
CY2018Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18500	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14750	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
CY2018Q4	lxrp	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	145880	USD
CY2019Q1	lxrp	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	362799	USD
CY2019Q2	lxrp	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	228444	USD
CY2019Q3	lxrp	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	59000	USD
CY2018Q4	lxrp	Accumulated Other Comprehensive Loss AccumulatedOtherComprehensiveLoss	14247	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	131000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	103500	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	1000000	USD
CY2019Q4	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-17450	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-47148	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-29272	USD
CY2019Q2	lxrp	Warrants Issued For Service WarrantsIssuedForService	52817	USD
CY2019Q4	lxrp	Warrants Issued For Service WarrantsIssuedForService	70752	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2020Q2	lxrp	Territory License Fee Receivable TerritoryLicenseFeeReceivable	141370	USD
CY2019Q3	lxrp	Territory License Fee Receivable TerritoryLicenseFeeReceivable	106000	USD
CY2020Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	95632	USD
CY2019Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	161418	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4264	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	371	USD
CY2020Q2	lxrp	Number Of Warrants Issued NumberOfWarrantsIssued	8866211	shares
CY2020Q2	lxrp	Issue Price Of Units Issued IssuePriceOfUnitsIssued	0.23
CY2020Q2	lxrp	Fair Value Of Warrants Issued As Share Issue Cost FairValueOfWarrantsIssuedAsShareIssueCost	2039229	USD
	lxrp	Fair Value Of Warrants Issued As Share Issue Cost FairValueOfWarrantsIssuedAsShareIssueCost	128329	USD
	lxrp	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	10689956	shares
	lxrp	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	2859914	USD
	lxrp	Number Of Shares Issued In Exercise Of Options And Private Placement NumberOfSharesIssuedInExerciseOfOptionsAndPrivatePlacement	10799956	shares
	lxrp	Value Of Shares Issued In Exercise Of Options And Private Placement ValueOfSharesIssuedInExerciseOfOptionsAndPrivatePlacement	2870914	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3238000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.32
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.39
CY2020Q2	lxrp	Life Years LifeYears	P5Y
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4800000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5003000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5548000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.89
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.40
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1415000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4193000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.66
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.98
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.15
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.10
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2048000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4848000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M23D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	71000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5282000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.39
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y3M21D
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	71000	USD
	lxrp	Related Party Transaction Amounts Of Transaction In Cash RelatedPartyTransactionAmountsOfTransactionInCash	498490	USD
	lxrp	Related Party Transaction Amounts Of Transaction In Cash RelatedPartyTransactionAmountsOfTransactionInCash	397939	USD
	lxrp	Non Cash NonCash	661109	USD
	lxrp	Non Cash NonCash	225436	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1159599	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	623375	USD
CY2020Q2	us-gaap	Prepaid Insurance PrepaidInsurance	17930	USD
CY2019Q3	us-gaap	Prepaid Insurance PrepaidInsurance	29784	USD
CY2020Q2	lxrp	Prepaid Legal Fees PrepaidLegalFees	12338	USD
CY2019Q3	lxrp	Prepaid Legal Fees PrepaidLegalFees	0	USD
CY2020Q2	us-gaap	Marketable Securities MarketableSecurities	25000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-18198	USD
	lxrp	Payment For Private Placement Fees PaymentForPrivatePlacementFees	156288	USD
	lxrp	Payment For Net Receipt Amount Of Private Placement PaymentForNetReceiptAmountOfPrivatePlacement	2703626	USD

Files In Submission

Name	View Source	Status
0001640334-20-001650-index-headers.html	Edgar Link	pending
0001640334-20-001650-index.html	Edgar Link	pending
0001640334-20-001650.txt	Edgar Link	pending
0001640334-20-001650-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrp-20200531.xml	Edgar Link	completed
lxrp-20200531.xsd	Edgar Link	pending
lxrp-20200531_cal.xml	Edgar Link	unprocessable
lxrp-20200531_def.xml	Edgar Link	unprocessable
lxrp-20200531_lab.xml	Edgar Link	unprocessable
lxrp-20200531_pre.xml	Edgar Link	unprocessable
lxrp_10q.htm	Edgar Link	pending
lxrp_10qimg48.jpg	Edgar Link	pending
lxrp_ex311.htm	Edgar Link	pending
lxrp_ex312.htm	Edgar Link	pending
lxrp_ex321.htm	Edgar Link	pending
lxrp_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LEXX
Lexaria Bioscience Corp. Stock $lexx

2020 Q3 Form 10-Q Financial Statement

#000164033420001650 Filed on June 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX Lexaria Bioscience Corp. Stock $lexx

2020 Q3 Form 10-Q Financial Statement

#000164033420001650 Filed on June 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX
Lexaria Bioscience Corp. Stock $lexx